Dublin, Ireland, July 25th, 2018 – ICON plc (NASDAQ: ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the second quarter ended June 30, 2018.
CEO Dr. Steve Cutler commented, “During the quarter we delivered a new record $600 million of net business wins, representing a quarterly book to bill of 1.27. Market demand fundamentals continue to remain positive and supported by a strong trailing twelve month book to bill of 1.29, our backlog grew to $5.2 billion, an increase of 16% year over year. In quarter 2 revenues grew 10% over the same period in 2017 and along with continued efficient cost management and a quarterly effective tax rate of 10%, we delivered further value to our shareholders with earnings per share increasing by 18%. We are increasing our revenue guidance to a range of $2,560 - $2,640 million and our earnings guidance to a range of $5.98 - $6.12.”
Second Quarter 2018 Results
Excluding the impact of ASC 606, gross business wins in the second quarter were $720 million and cancellations were $120 million. This resulted in net business wins of $600 million, a book to bill of 1.27.
Reported revenue for quarter 2 was $641.6 million. Excluding the impact of ASC 606, quarter 2 revenue increased to $473.9 million from $431.0 million in the same quarter last year, an increase of 10.0%.
Reported income from operations in the quarter before non-recurring charges was $94.4 million or 14.7% of revenue. Excluding the impact of ASC 606, income from operations before non-recurring charges increased by 11.9% to $96.0 million, or 20.2% of revenue, compared to $85.8 million or 19.9% for the same quarter last year.
Reported net income for the quarter before non-recurring charges was $82.9 million or 12.9% of revenue. Excluding the impact of ASC 606, net income before non-recurring charges increased by 17.7% to $84.3 million, compared with $71.6 million in the same quarter last year.
Reported earnings per share on a diluted basis before non-recurring charges was $1.51. Excluding the impact of ASC 606, diluted earnings per share before non-recurring charges increased by 17.6% to $1.54, compared to $1.31 per share for the same quarter last year.
Full consolidated income statements and summary balance sheet data can be read here
Year to date 2018 Results
Excluding the impact of ASC 606, gross business wins year to date were $1,423 million and cancellations were $233 million. This resulted in net business wins of $1,190 million, a book to bill of 1.27.
Year to date reported revenue was $1,261.7 million. Excluding the impact of ASC 606, year to date revenue increased to $936.5 million from $863.0 million in the same quarter last year, an increase of 8.5%.
Reported income from operations year to date, before non-recurring charges was $186.1 million or 14.7% of revenue. Excluding the impact of ASC 606, income from operations before non-recurring charges increased by 10.1% to $188.7 million, or 20.2% of revenue, compared to $171.4 million or 19.9% for the same quarter last year.
Reported net income year to date, before non-recurring charges was $161.0 million or 12.8% of revenue. Excluding the impact of ASC 606, net income before non-recurring charges increased by 14.2% to $163.3 million, compared with $143.0 million in the same quarter last year.
Reported earnings per share on a diluted basis before non-recurring charges was $2.93. Excluding the impact of ASC 606, diluted earnings per share before non-recurring charges increased by 14.6% to $2.98, compared to $2.60 per share for the same quarter last year.
We continued our share repurchase program in the quarter, buying $16.0 million worth of stock at an average price of $134.22 per share.
Days sales outstanding, comprising accounts receivable and unbilled revenue less payments on account, were 49 days at June 30, 2018, compared with 51 days at the end of March 2018 and 53 days at the end of June 2017.
Cash generated from operating activities for the quarter was $39.2 million. Capital expenditure for the quarter was $8.9 million. As a result, at June 30, 2018, the company had net cash of $23.9 million, compared to net cash of $4.6 million at March 31, 2018 and net debt of $33.8 million at the end of June 2017.
During the quarter the company recorded a charge of $12.5 million in relation to restructuring costs. US GAAP income from operations after these items amounted to $81.9 million or 12.8% of revenue. US GAAP net income for the quarter was $71.9 million or $1.31 per diluted share.
The new revenue recognition standard (ASU No. 2014-09) ‘Revenue from Contracts with Customers’ was effective for ICON plc from January 1, 2018. ICON has elected to adopt the new standard under the cumulative effect transition method. Under this transition method, the new standard is applied from January 1, 2018 without restatement of comparative period amounts. The cumulative effect of initially applying the new standard is reflected as an adjustment to opening equity at the date of application. Results for the three and six months ended June 2017 are therefore presented under the previous revenue recognition accounting principles.
In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), this press release contains certain non-GAAP financial measures, including non-GAAP operating and net income and non-GAAP diluted earnings per share. While non-GAAP financial measures are not superior to or a substitute for the comparable GAAP measures, ICON believes certain non-GAAP information is useful to investors for historical comparison purposes.
ICON will hold its second quarter conference call tomorrow, July 26, 2018 at 09:00 EDT [14:00 Ireland & UK]. This call and linked slide presentation can be accessed live from our website at http://investor.iconplc.com. A recording will also be available on the website for 90 days following the call. In addition, a calendar of company events
, including upcoming conference presentations, is available on our website, under “Investors
”. This calendar will be updated regularly.
This press release contains forward-looking statements. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, as well as economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are available on the SEC's website at http://www.sec.gov
ICON plc is a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 93 locations in 37 countries and has approximately 13,650 employees. Further information is available at www.iconplc.com
Source: ICON plc
Contact: Investor Relations +1888 381 7923 or
Brendan Brennan Chief Financial Officer +353 1 291 2000
Jonathan Curtain Vice President Corporate Finance and Investor Relations +1 215 616 3000
All at ICON.